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Abstract
Background:  Metallothionein (MT) protein expression deficiency has been implicated in
carcinogenesis while MT over expression in tumors is indicative of tumor resistance to anti-cancer
treatment. The purpose of the study was to examine the expression of MT expression in human
renal cell carcinoma (RCC) and to correlate MT positivity, the pattern and extent of MT expression
with tumor histologic cell type and nuclear grade, pathologic stage and patients' survival.
Patients and methods: The immunohistochemical expression of MT was determined in 43
formalin-fixed and paraffin-embedded RCC specimens, using a mouse monoclonal antibody that
reacts with both human MT-I and MT-II. Correlation was sought between immunohistochemical
(MT positivity, intensity and extension of staining) and clinico-pathological data (histological cell
type, tumor nuclear grade, pathologic stage and patients' survival).
Results: Positive MT staining was present in 21 cases (49%), being mild/moderate and intense in 8
and 13 cases, respectively. The pattern was cytoplasmic in 7 cases and was both cytoplasmic and
nuclear in 14 cases. MT expression in a percentage of up to 25% of tumor cells (negative MT
staining included) was observed in 31 cases, in a percentage 25–50% of tumor cells in 7 cases, and
in a percentage of 50–75% of tumor cells in 5 cases. There was no significant correlation of MT
intensity of staining to histological type, stage and patients' survival, while it was inversely correlated
to higher tumor nuclear grade. MT extent of staining did not correlate with histological type,
nuclear grade, and pathologic stage while a statistically significant association was found with
patients' survival.
Conclusions: The inverse correlation between MT staining intensity and tumor nuclear grade in
RCC suggests a role of MT in tumor differentiation process. Since extent of MT expression is
inversely correlated with survival it may be possibly used as a clinical prognostic parameter.
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Background
Metallothioneins (MTs) were firstly discovered by Mar-
goses and Valle in 1957 [1] as cadmium (Cd) binding pro-
teins. Later, Piscator [2] documented a marked increase of
MT in Cd exposed rabbits, as a metal detoxification mech-
anism. MTs are a family of heavy metal binding proteins
with a large degree of sequence homology that have been
described in most vertebrate and invertebrate species.
They are single-chain proteins, with molecular weight of
approximately 6000 Da, characterized by a very high pro-
portion of cysteine residues (30%), resulting in several
high affinity Cd and/or zinc (Zn) binding sites [3]. There
are two major isoforms, referred to as MT-I and MT-II [4],
resolvable through ion exchange chromatography, that
have closely related but distinct amino acid sequences and
are distributed in most adult mammalian tissues.
Recently, a further charge-separable MT isoform (MT-0)
[4], and genes for two MT isoforms with restricted tissue
distribution MT-III (brain neurons) [5,6] and MT-IV
(stratified epithelia) [7] have been described. The poten-
tial for wider tissue distribution of MT-III was suggested
by recent studies demonstrating the presence of MT-III
mRNA and protein in the adult and developing human
kidney [8,9].
MT-I and MT-II isoforms are usually expressed in low lev-
els, but are inducible by a variety of metal ions, hormones,
inflammatory cytokines and xenobiotics [10-12]. Induc-
tion of MTs is important in detoxification and metal ion
homeostasis [9], in protection against reactive oxygen spe-
cies [10] and in tissue regeneration [13-15]. MT expres-
sion deficiency implicated in carcinogenesis [16] and
possible relation of MT over expression and resistance of
tumors to anti-cancer therapy [17] has provided evidence
of the importance of MT expression in cancer. MT over
expression, detected immunohistochemically, has been
described in a variety of human tumors, in relation to dif-
ferent stages of tumor development and progression [18].
The involvement of MT and Zn, in processes such as p53
gene activation and protein structure has been referred
[16,19]. There is evidence that some human tumors con-
tain high levels of MT, nevertheless, the importance of MT
expression in carcinogenic evolution and in patients' sur-
vival is not yet fully understood.
In organs such as kidney, colon and liver, normally impli-
cated in metal ions homeostasis, MT protein is apparently
expressed. It would be of great scientific importance to
elucidate the pattern of MT expression in tumors devel-
oped from these organs, since it could not only delineate
the role of MT in carcinogenic transformation but could
also provide prognostic information for patients' out-
come. The aim of the present study was to examine the
expression of MT in human renal cell carcinoma (RCC)
and to correlate the MT positivity, the pattern and extent
of MT expression with tumor histological cell type and
nuclear grade, pathologic stage and patients' survival.
Patients and methods
Forty three consecutive patients, 31 men and 12 women,
who underwent nephrectomy for RCC comprised the
group of our study. Their age ranged from 33 to 85 years
(mean age 59.6 ± 11.1). Tumors were histologically clas-
sified as clear cell type in 32 cases, papillary type in 2
cases, chromophobe cell type in 4 cases and sarcomatoid
type in 5 cases. The 8, 2, 16, 6 and 9 tumors were patho-
logically staged as T1 or T2N0M0, T2N+M0, T3N0M0,
T3N+M0 and T4N+M+, respectively as per the TNM clas-
sification [20]. The grade of nuclear atypia according to
Fuhrman Grading system [21] was: grade I in 11 cases,
grade II in 15 cases, grade III in 6 cases, and grade IV in 11
cases. The patients were followed up from 2 up to 144
months (5 lost in follow up), mean 65.4 months, median
39 months.
Immunohistochemistry
Sections of 5 µm thickness were deparaffinized in xylene
and rehydrated in graded alcohol series. To remove the
endogenous peroxidase activity, sections were treated
with freshly prepared 0.3% (v/v) hydrogen peroxide in
methanol in dark, for 30 min, at room temperature. Non-
specific antibody binding was then blocked using normal
rabbit serum (Dakopatts, Glostrup, Denmark) diluted 1:5
in phosphate buffered saline (PBS), for 20 minute. A
mouse (IgG1k) monoclonal antibody that reacts with
both human MT-I and -II isoforms (Zymed, San Fran-
cisco, California, USA) was used in this study. The sec-
tions were then incubated for 1 hour, at room
temperature, with the primary antibody diluted 1:50 in
PBS. After three washes with PBS, sections were incubated
for 30 minute at room temperature with rabbit, peroxi-
dase conjugated, anti-mouse serum (Dakopatts) diluted
1:200 in PBS and rinsed three times with PBS. Sections
were then incubated with swine, peroxidase conjugated,
anti-rabbit serum (Dakopatts) diluted 1:100 in PBS and
rinsed three more times with PBS. The resultant immune
peroxidase complexes were developed in 0.5% (v/v) 3,3'-
diaminobenzidine hydrochloride (DAB; Sigma, Saint
Louis, MO, USA) in PBS containing 0.03% (v/v) hydrogen
peroxide. Sections were counterstained with Harris' hema-
toxylin and mounted in gelatin (Sigma). Control slides
included in MT immunostaining procedure consisted of
specific tissues previously shown to express MT (lung can-
cer) as positive controls, whereas the primary antibody
was replaced by PBS in the case of negative controls.
Scoring system
The stained sections were independently assessed by the
pathologists (A.K., S.T., E.M.) without prior knowledge of
the clinical data as previously described [22]. SpecimensWorld Journal of Surgical Oncology 2005, 3:5 http://www.wjso.com/content/3/1/5
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were considered as "positive" for MT when more than 5%
of tumor cells within the section were positively stained.
The intensity of staining was graded as mild (+), moderate
(++), and intense (+++). To further evaluate the impor-
tance of staining extent, cases were stratified into 3 groups
according to the percentage of cells staining positive for
MT: group A, 0–25%; group B, 26–50%; and group C,
>50% of MT positive cells. The pattern of MT staining was
also characterized as cytoplasmic only, nuclear only, and
both cytoplasmic and nuclear.
Statistical analysis
Correlation between immunohistochemical data (MT
intensity and extent of staining) and clinicopathological
data (histologic cell type, nuclear grade, pathologic stage)
was assessed using the Chi-square test. The association of
intensity and extent of MT immunohistochemical stain-
ing with survival was determined by comparing Kaplan-
Meier survival curves constructed for different patient
groups, and were compared using the log-rank test.
Results
Tubular cells but not glomeruli and interstitial cells of
normal autologous renal tissue stained positive (both in
the nucleus and the cytoplasm) for MT, although the
intensity and extent varied significantly. Positive MT
expression was prominent in 21 out of 43 cases (49%),
while 22 out of 43 ones (51%) were MT negative. As far as
the intensity of staining is concerned, low/moderate
intensity was observed in 8 cases, while intense staining
was evident in 13 cases. The pattern of positive MT immu-
nostaining observed was either cytoplasmic (7 out of 21
cases, 33.3%) or cytoplasmic and nuclear (14 out of 21
cases, 66.6%). In certain cases of clear cell RCC membra-
nous staining was also observed. Nuclear pattern of stain-
ing only, was not observed in any of the RCC cases
examined (Figure 1). The extent of MT expression in a per-
centage of up to 25% of tumor cells (negative MT staining
included) was observed in 31 out of 43 cases, in a percent-
age 25 up to 50% of tumor cells in 7 cases, and in a per-
centage of 50–75% of tumor cells in 5 cases.
There was no significant difference between MT intensity
of staining and the histological types of RCC cases exam-
ined (χ2 = 5.61, p = 0.46). No statistically significant dif-
ferences were also observed between MT intensity of
staining and stage (χ2 = 9.24, p = 0.32), or patients' sur-
vival (log rank test: 4.75, p = 0.09) in the cases of RCC
examined (Figure 2). Statistically significant correlation
was found between MT intensity of staining and histolog-
ical grade, where higher intensity of staining was found in
cases presenting high histological grade (χ2 = 13.63, p =
0.03). However, no such correlation was found in the case
of clear cell RCC (χ2 = 4.75, p = 0.57).
Non statistical correlation was found among MT extent of
staining and histological types (χ2 = 2.54, p = 0.86), stage
(χ2 = 7.12, p = 0.52) and grade (χ2 = 6.24, p = 0.39) of
RCC cases examined. Statistically significant inverse corre-
lation was found between MT extent of staining and
patients' survival (log rank test: 6.59, p = 0.037) (Figure
3). Again, this was not observed in case all other histolog-
ical types but clear cell RCC were excluded (log rank test
3.36, p = 0.186).
Discussion
MT expression has been observed in different types of
human tumors [18,22], including neoplasias of the uro-
genital tract [23-28]. However, the biological mechanisms
underlying MT over expression in tumors, or the conse-
quences of this over expression are not currently well
understood. MT is highly expressed in fetal life [10]; the
reappearance of this fetal characteristic in tumors suggests
its participation in cellular growth and differentiation
[16,18,19].
Developing and adult kidneys consistently express MT-I
and MT-II mRNA [29] and the corresponding protein
[28], while the MT-III isoform is also expressed in devel-
oping renal tissue, adult proximal tubule and renal cell
carcinoma cell lines [8,9]. The MT-0 isoform is absent in
adult kidneys but it can be found in nonneoplastic tissue
from renal and transitional cell carcinoma [30]. The iso-
form specific expression of MT in RCC has not been so far
investigated. Using a monoclonal antibody that reacts to
both MT-I and MT-II, we demonstrated positive immuno-
reaction in 49% of our RCC cases, a percentage close to
the 55.7% reported by Tüzel et al [24], using the same
antibody. Zhang and Takenaka [24] used another com-
mercially available monoclonal antibody with unspeci-
fied specificity towards different MT isoforms and found
positive immunoreaction for the MT protein in 33% of
their cases, while such report is not included in the study
of Izawa et al [23] who used a polyclonal antibody pre-
pared by their own laboratory.
The cytoplasm and nucleus of normal and malignant cells
may both express MT but there is no conclusive data on
the functional significance of their subcellular distribu-
tion. The majority of the cases in our study expressed MT
in both cytoplasm and nucleus, the expression being cyto-
plasmic only in one third of the cases. Analogous pattern
has been reported in other studies [23-25] while the mem-
branous staining observed in some of our cases as well as
in two previous series [24,25] could be explained by the
nature of clear cell carcinoma. Differential subcellular
expression of MT may be related to either cell prolifera-
tion or the induction of apoptosis [31,32]. Recently,
Kondo et al [33] pointed out the importance of subcellu-
lar distribution of MT in drug resistant-prostatic cancerWorld Journal of Surgical Oncology 2005, 3:5 http://www.wjso.com/content/3/1/5
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cells, in which the nuclear MT expression rather the cyto-
plasmic counterpart seems to predominantly confer resist-
ance to cisplatin. On the other hand, nuclear pattern of
MT immunostaining has already been correlated with cel-
lular response to stress stimuli [34]. The function of MT to
protect the cell from apoptosis could be an explanation
for MT over expression observed in high grade cases of
RCC [24], as MT is not etiologically correlated with the
apoptotic process.
In certain tumors MT over expression has been associated
with unfavorable prognostic characteristics such as
advanced stage and poor differentiation [18]. In our
study, MT intensity of staining did not correlate with stage
while it showed an inverse correlation with histological
grade. Our results are in accordance to those of other
investigators [23,25], who also found an inverse relation-
ship between MT immunoreactivity and tumor grade. In
contrast, Zhang and Takenaka [24] reported positive asso-
ciations between MT expression and tumor grade. The
inverse relationship between MT immunohistochemical
expression and tumor grade may suggest a role of MT in
cellular growth and differentiation, and reflect alterations
of intracellular processes leading to a gradual decline of
Zn storage and to the subsequent decrease in MT expres-
sion. Although no association was found between MT
staining intensity and survival, the reduced extent of MT
expression significantly correlated with prolonged
Detection of MT expression by immunohistochemistry Figure 1
Detection of MT expression by immunohistochemistry. Intense membranous, cytoplasmic and nuclear staining in a case of 
clear cell type RCC (x330).World Journal of Surgical Oncology 2005, 3:5 http://www.wjso.com/content/3/1/5
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survival as reported elsewhere [25]. The extent of MT
expression may offer an additional, prognostic factor in
patients suffering from RCC.
MT concentrations might also prove useful in predicting
the efficacy of a particular cancer treatment protocols. Sev-
eral types of transformed cells enriched for MT have been
shown to exhibit greater resistance to chemotherapeutic
agents [17]. In this context, the thiolate sulfur of the
cysteine residues are thought to act as sacrificial scaven-
gers for radicals and alkylyating agents [10]. Thus, MT
might serve as a Cu and Zn reservoir, where their supply
may negatively affect the growth of tumor cells. MT could
also participate in tumorigenesis by sequestering and then
donating these essential bivalent cations to proteins of
tumor cells in order to meet metabolic requirements [35].
Conclusions
The current data on the expression of MT in RCC cases
examined emphasize the necessity to investigate larger
numbers of patients with RCC comparing the staining
profile of different MT isoforms with other clinico-patho-
logical parameters and survival status of patients. Cur-
rently, it is unknown whether the presence of MT in renal
carcinoma cells is related to the induction or inhibition of
apoptosis or plays an active role in cell proliferation. Since
Cancer-specific survival of patients according to intensity of staining for MT (no staining, green line; mild/moderate staining,  blue line; intense staining, red line) Figure 2
Cancer-specific survival of patients according to intensity of staining for MT (no staining, green line; mild/moderate staining, 
blue line; intense staining, red line). No statistically significant difference was detected (p = 0.09).World Journal of Surgical Oncology 2005, 3:5 http://www.wjso.com/content/3/1/5
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cytokines may also induce MT expression and immuno-
therapy is the only, albeit with limited efficacy, available
treatment for RCC, the intensity and extent of MT immu-
nostaining should be studied in correlation to the
immune status of RCC patients before and after immuno-
therapy. Thus, it will be possible to elucidate the potential
role of MT in renal cell carcinogenesis, as well as its clini-
cal usefulness as a tumor marker and as a tool for selecting
patients for adjuvant immunotherapy.
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